Fasting Insulin: Evidence-Based Ways to Improve Your Number

What Fasting Insulin Actually Measures

Fasting insulin is a blood test drawn after at least eight hours without food or caloric beverages. It tells you how much insulin your pancreas is secreting at rest, when there is no glucose load to process. A high resting level almost always means your cells are responding poorly to insulin, so your pancreas is compensating by producing more.

Glucose and HbA1c can stay normal for years while fasting insulin is already elevated. This is why clinicians who specialize in metabolic health often describe fasting insulin as an early warning signal, one that glucose alone misses.

Why the "Normal" Range Is Contested

Conventional lab reference ranges vary by assay but most laboratories flag values above 25 µIU/mL as high. The American Diabetes Association does not specify a single fasting insulin cutoff in its Standards of Care, because assay standardization remains a problem across laboratories.

Functional and integrative practitioners frequently use a tighter target of <10 µIU/mL as "optimal," based on population data showing that cardiovascular risk rises progressively above that level. A 2019 analysis in Diabetes Care found that fasting insulin above 9.4 µIU/mL was associated with incident type 2 diabetes independent of fasting glucose, supporting this tighter threshold.

The HOMA-IR Calculation

Your clinician may calculate HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) from the same blood draw. The formula is: fasting insulin (µIU/mL) × fasting glucose (mmol/L) divided by 22.5. A HOMA-IR above 2.5-3.0 is broadly accepted as indicating insulin resistance in most adult populations, though a 2015 systematic review in PLOS ONE noted that optimal cutoffs differ by ethnicity and sex.

How Fasting Insulin Differs Across a Woman's Life

Hormones do not sit still. Your estrogen, progesterone, testosterone, and cortisol levels change every decade, and they all interact with insulin signaling.

Reproductive Years and the Menstrual Cycle

Insulin sensitivity is not constant across your cycle. Research published in Fertility and Sterility showed that insulin sensitivity is highest in the follicular phase and decreases in the luteal phase as progesterone rises. This means a fasting insulin drawn on day 21 of a 28-day cycle may read higher than the same test drawn on day 5, even if nothing else has changed. If you are tracking your metabolic health carefully, try to draw fasting insulin at the same cycle phase each time.

PCOS: The Condition Where This Test Matters Most

Between 65 and 70% of women with PCOS have insulin resistance, and many are lean. PCOS amplifies the pancreatic response to any given glucose load, driving fasting insulin higher independent of body weight. ACOG Practice Bulletin No. 194 recognizes insulin resistance as central to PCOS pathophysiology and recommends lifestyle modification, and metformin when indicated, as first-line interventions.

High fasting insulin in PCOS stimulates ovarian theca cells to produce excess androgens. Lowering fasting insulin is therefore not just a metabolic goal; it can reduce testosterone, improve ovulation, and restore cycle regularity.

Perimenopause and Menopause

The decline in estradiol that begins in perimenopause directly worsens hepatic insulin sensitivity. A 2021 paper in Menopause found that HOMA-IR increased by a mean of 0.44 units across the menopausal transition even after controlling for BMI change. This means you may see your fasting insulin creep up in your late 40s with no obvious dietary change, and that is physiology, not failure.

Menopausal hormone therapy (MHT), particularly transdermal estradiol, appears to partially offset this insulin resistance. A randomized trial in the Journal of Clinical Endocrinology and Metabolism showed that transdermal estradiol improved insulin sensitivity while oral estrogen did not, likely because oral estrogen undergoes first-pass hepatic metabolism. Route of administration matters here.

Postpartum Period

After delivery, insulin sensitivity rapidly improves for most women. Women who had gestational diabetes, however, carry a seven-fold increased lifetime risk of type 2 diabetes and benefit from annual fasting glucose testing. Fasting insulin checked at the 6-12 week postpartum visit can identify persistent insulin resistance before glucose abnormalities appear, though this is not yet standard protocol at all practices.

What a High Fasting Insulin Means

A high fasting insulin nearly always signals insulin resistance: your cells require more insulin to accomplish the same glucose uptake. It often appears years before fasting glucose rises, before HbA1c budges, and before a type 2 diabetes diagnosis.

Associated conditions in women include:

• PCOS (as described above)
• Non-alcoholic fatty liver disease (NAFLD), now termed metabolic-associated steatotic liver disease
• Acanthosis nigricans (darkening at the neck, armpits, or groin)
• Hormonal acne and hirsutism
• Difficulty losing weight despite caloric restriction
• Female pattern hair loss driven by androgen excess secondary to high insulin
• Elevated triglycerides with low HDL cholesterol

The Endocrine Society's 2021 Clinical Practice Guideline on Obesity in Adults notes that insulin resistance is a key driver of adipose tissue dysfunction, and that treating insulin resistance often improves body composition outcomes independent of caloric deficit.

What a Low Fasting Insulin Means

Low fasting insulin (below roughly 2-3 µIU/mL) is less commonly discussed but clinically relevant. It may indicate:

• Type 1 diabetes or latent autoimmune diabetes in adults (LADA), where beta-cell destruction reduces insulin secretion
• Prolonged low-carbohydrate or ketogenic eating, which physiologically reduces insulin requirements
• Pancreatic insufficiency or damage

A very low fasting insulin in a woman who is not intentionally eating low-carbohydrate and who has elevated glucose is a red flag warranting antibody testing (GAD65, IA-2, zinc transporter 8) to rule out autoimmune diabetes. This pattern differs from the high-insulin insulin resistance picture and requires a different clinical approach entirely.

Evidence-Based Strategies to Lower a High Fasting Insulin

The strategies below are ranked by evidence quality in women, not by ease or popularity. Each one has at least one randomized controlled trial or meta-analysis directly measuring fasting insulin or HOMA-IR as an outcome.

1. Dietary Carbohydrate Quality and Load

Reducing the glycemic load of your diet is the single most consistently studied lever. You do not have to go zero-carbohydrate. Replacing refined grains and added sugars with whole grains, legumes, and non-starchy vegetables reduces postprandial insulin spikes and, over weeks, lowers baseline fasting insulin.

The PREDIMED-Plus trial, which enrolled over 6,800 participants, reported a 0.9-unit reduction in HOMA-IR at 12 months with an energy-reduced Mediterranean diet relative to usual care. Subgroup analysis showed the benefit held in women across the BMI range tested.

A 2021 meta-analysis in Nutrients of 18 RCTs found that low-glycemic-index diets reduced fasting insulin by a mean of 2.06 µIU/mL compared to control diets. The benefit appeared within 4 weeks and was sustained at 6 months.

Practical targets:

• Limit added sugars to <25 g/day (the American Heart Association threshold for women)
• Prioritize legumes, intact whole grains, and berries over refined breads and juice
• Distribute carbohydrates across meals rather than concentrating them at one sitting

2. Time-Restricted Eating

Compressing your eating window to 8-10 hours allows insulin levels to remain low for a longer overnight period. A 16-week RCT published in the New England Journal of Medicine in 2022 compared caloric restriction alone to time-restricted eating (8-hour window) plus caloric restriction in adults with obesity. Both groups lost similar weight, but fasting insulin fell more in the time-restricted group.

For women with PCOS specifically, a pilot RCT in Fertility and Sterility found that a 10-hour eating window over 5 weeks reduced fasting insulin by 28% and improved testosterone levels. The sample was small (n=18), so these numbers should be interpreted cautiously, but the mechanistic direction is consistent with larger metabolic literature.

Time-restricted eating is generally safe during the reproductive years. It is not appropriate in pregnancy or during active breastfeeding, where consistent caloric intake across the day supports milk production and fetal growth.

3. Resistance Training

Skeletal muscle is the primary site of insulin-stimulated glucose disposal. Building or preserving muscle mass directly improves insulin sensitivity. A meta-analysis in Sports Medicine of 11 RCTs found that resistance training reduced HOMA-IR by a mean of 0.89 units, an effect size comparable to metformin in some populations.

For women, this matters across every life stage:

• Reproductive years: Two to three sessions per week of progressive resistance training improve insulin sensitivity and reduce androgen levels in PCOS, per a 2020 meta-analysis in Obesity Reviews.
• Perimenopause and postmenopause: Muscle mass declines at roughly 1-2% per year after 50. Resistance training counteracts this, preserving the metabolic buffer that keeps fasting insulin in range.

You do not need a gym. Bodyweight squats, lunges, push-ups progressed over time, and resistance bands all count if the effort is sufficient to cause muscle fatigue within 8-15 repetitions.

4. Aerobic Exercise and HIIT

Aerobic exercise acutely depletes muscle glycogen, creating an insulin-independent glucose uptake window that persists for hours. High-intensity interval training (HIIT) produces a larger and faster improvement in insulin sensitivity per minute of exercise than moderate continuous activity. A 2019 Cochrane review of exercise interventions for women with PCOS confirmed that both HIIT and moderate aerobic exercise significantly reduced fasting insulin and HOMA-IR.

The practical recommendation is to combine both modalities: two to three days of resistance training plus two days of moderate aerobic activity, with one HIIT session substituted for one aerobic session when time is limited.

5. Sleep Duration and Quality

Sleep is the most underrated metabolic variable in clinical practice. A landmark study in Annals of Internal Medicine showed that reducing sleep from 8.5 to 5.5 hours over two weeks increased fasting insulin by 14% and reduced insulin sensitivity by 20%. These changes occurred without any dietary modification.

Women are more vulnerable to sleep disruption during perimenopause due to vasomotor symptoms and sleep-disordered breathing. Prioritizing sleep hygiene, and treating obstructive sleep apnea when present, is a direct intervention on fasting insulin, not just a wellness recommendation.

6. Stress and Cortisol Management

Chronic cortisol elevation drives hepatic glucose output and suppresses peripheral insulin sensitivity. Women in high-stress environments show higher HOMA-IR independent of diet and exercise, per a 2020 study in Psychoneuroendocrinology.

Mindfulness-based stress reduction (MBSR) over 8 weeks reduced cortisol awakening response and improved HOMA-IR in perimenopausal women in a small RCT published in Menopause. The effect size was modest, but stress management compounds with the other strategies above.

7. Targeted Supplements With Actual Evidence

Most supplements marketed for insulin sensitivity have thin evidence. Three have reasonable data in women:

• Inositol (myo-inositol and d-chiro-inositol): A 2019 meta-analysis in Reproductive BioMedicine Online of 13 RCTs found myo-inositol significantly reduced fasting insulin and improved ovulation rates in women with PCOS. Typical studied doses range from 2,000 to 4,000 mg/day of myo-inositol.
• Berberine 500 mg three times daily: A 2012 meta-analysis in Evidence-Based Complementary and Alternative Medicine showed berberine reduced fasting insulin comparably to metformin in several small trials, though larger head-to-head data in women specifically are limited.
• Magnesium: Epidemiological data consistently link low magnesium intake with higher insulin resistance. A 2016 meta-analysis in Nutrients found magnesium supplementation significantly reduced HOMA-IR in insulin-resistant participants. Dietary magnesium (leafy greens, nuts, seeds) is preferable to supplementation where achievable.

Note: Berberine inhibits CYP3A4 and may interact with hormonal contraceptives; discuss with your clinician before starting.

Medication Options

When lifestyle changes are insufficient, or when insulin resistance is driving an urgent clinical problem (anovulation, gestational diabetes risk, progressive prediabetes), medications add meaningful benefit.

Metformin

Metformin is the most studied insulin-sensitizing drug in women. It reduces hepatic glucose output and lowers fasting insulin by roughly 20-30% in women with PCOS or prediabetes. ACOG Practice Bulletin 194 supports metformin use in PCOS for metabolic indications. Standard dosing starts at 500 mg daily with food, titrated to 1,500-2,000 mg/day over four to eight weeks to minimize GI side effects.

GLP-1 Receptor Agonists

Semaglutide and liraglutide reduce fasting insulin indirectly by improving overall insulin sensitivity and reducing body weight and visceral fat. The SCALE trial with liraglutide 3.0 mg showed significant reductions in HOMA-IR at 56 weeks in adults with obesity. Semaglutide trials show comparable metabolic effects. These medications are approved for chronic weight management and are increasingly used in women with PCOS who need more than metformin.

Menopausal Hormone Therapy

As noted above, transdermal estradiol improves insulin sensitivity in postmenopausal women and may modestly lower fasting insulin. This is a secondary benefit, not the primary indication, but it is worth discussing with your clinician if you are perimenopausal or postmenopausal and your fasting insulin is trending up.

Pregnancy, Lactation, and Contraception Considerations

Fasting insulin is a lab test, not a drug, so there is no pregnancy or lactation contraindication to checking the number. There are, however, several clinical points every pregnant or breastfeeding woman should know.

Pregnancy: Insulin resistance rises physiologically in the second and third trimesters, driven by placental hormones including human placental lactogen. The American Diabetes Association's 2024 Standards of Care recommends gestational diabetes screening at 24-28 weeks using the oral glucose tolerance test. Fasting insulin is not used diagnostically in pregnancy, but a history of elevated pre-pregnancy fasting insulin is a meaningful risk factor for gestational diabetes and warrants earlier glucose monitoring.

Women with PCOS: PCOS carries a two- to three-fold increased risk of gestational diabetes. ACOG Practice Bulletin 190 recommends early glucose screening in women with PCOS risk factors.

Metformin in pregnancy: Metformin crosses the placenta. It is not FDA-approved for gestational diabetes but is used off-label in some practices and in women with PCOS who conceived on metformin. The MiG trial (NEJM 2008) found metformin non-inferior to insulin for glycemic control in gestational diabetes, though long-term offspring data remain a subject of ongoing research. Decisions about continuing or stopping metformin in pregnancy require individualized discussion with your OB-GYN or maternal-fetal medicine specialist.

Lactation: Metformin passes into breast milk in small amounts. A pharmacokinetic study in Diabetes Care found infant exposure of roughly 0.28% of the maternal weight-adjusted dose, considered low by most authorities. The Academy of Breastfeeding Medicine lists metformin as compatible with breastfeeding, but monitoring the infant for hypoglycemia is reasonable.

Inositol in pregnancy: Myo-inositol has been studied for gestational diabetes prevention. A 2018 RCT in AJOG found that 4,000 mg/day of myo-inositol from the first trimester reduced gestational diabetes incidence in women at risk. It is generally considered safe in pregnancy, though your clinician should be aware you are taking it.

Who This Approach Is Right For (and Who Needs a Different Conversation)

Lifestyle changes to lower fasting insulin are appropriate for nearly any woman whose result is above 10 µIU/mL in the absence of another explanation. The strategies above carry negligible risk and meaningful benefit across life stages.

Consider requesting additional workup before treating fasting insulin in isolation if:

• Your fasting insulin is below 3 µIU/mL and your glucose is elevated (consider LADA or type 1 workup)
• You have symptoms of Cushing syndrome (central weight gain, purple striae, moon face) because hypercortisolism raises insulin independently of lifestyle
• You are pregnant, where the clinical priority shifts to glucose management, not fasting insulin
• You are on antipsychotic medications, which directly impair insulin signaling and may require medication adjustment rather than lifestyle intensification alone

Women in perimenopause with rising fasting insulin despite good lifestyle habits deserve a dedicated conversation about MHT as a metabolic tool, not just a symptom treatment. This remains an under-discussed option.